Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.

Chai SJ, Fong SCY, Gan CP, Pua KC, Lim PVH, Lau SH, Zain RB, Abraham T, Ismail SM, Abdul Rahman ZA, Ponniah S, Patel V, Cheong SC, Lim KP.

Hum Vaccin Immunother. 2019;15(1):167-178. doi: 10.1080/21645515.2018.1520584. Epub 2018 Oct 12.

2.

Exclusion of alternative exon 33 of CaV1.2 calcium channels in heart is proarrhythmogenic.

Li G, Wang J, Liao P, Bartels P, Zhang H, Yu D, Liang MC, Poh KK, Yu CY, Jiang F, Yong TF, Wong YP, Hu Z, Huang H, Zhang G, Galupo MJ, Bian JS, Ponniah S, Trasti SL, See K, Foo R, Hoppe UC, Herzig S, Soong TW.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4288-E4295. doi: 10.1073/pnas.1617205114. Epub 2017 May 10.

3.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

4.

Comparative analysis of the root transcriptomes of cultivated sweetpotato (Ipomoea batatas [L.] Lam) and its wild ancestor (Ipomoea trifida [Kunth] G. Don).

Ponniah SK, Thimmapuram J, Bhide K, Kalavacharla VK, Manoharan M.

BMC Plant Biol. 2017 Jan 13;17(1):9. doi: 10.1186/s12870-016-0950-x.

5.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

6.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

7.

Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.

Chai SJ, Yap YY, Foo YC, Yap LF, Ponniah S, Teo SH, Cheong SC, Patel V, Lim KP.

PLoS One. 2015 Nov 4;10(11):e0130464. doi: 10.1371/journal.pone.0130464. eCollection 2015.

8.

Factors influencing the implementation of chronic care models: A systematic literature review.

Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A.

BMC Fam Pract. 2015 Aug 19;16:102. doi: 10.1186/s12875-015-0319-5. Review.

9.

Effectiveness of chronic care models: opportunities for improving healthcare practice and health outcomes: a systematic review.

Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A.

BMC Health Serv Res. 2015 May 10;15:194. doi: 10.1186/s12913-015-0854-8. Review.

10.

Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy.

Lim KP, Chun NA, Gan CP, Teo SH, Rahman ZA, Abraham MT, Zain RB, Ponniah S, Cheong SC.

Hum Vaccin Immunother. 2014;10(11):3214-23. doi: 10.4161/hv.29226.

11.

CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients.

Lim KP, Chun NA, Ismail SM, Abraham MT, Yusoff MN, Zain RB, Ngeow WC, Ponniah S, Cheong SC.

PLoS One. 2014 Aug 25;9(8):e103975. doi: 10.1371/journal.pone.0103975. eCollection 2014.

12.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE.

Ann Oncol. 2014 Sep;25(9):1735-42. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.

13.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE.

Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22. Review.

PMID:
24896623
14.

The GP2 peptide: a HER2/neu-based breast cancer vaccine.

Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA.

J Surg Oncol. 2012 Apr 1;105(5):452-8. doi: 10.1002/jso.21723. Review.

PMID:
22441896
15.

An eleven-vertex metallaborane with tetracapped pentagonal bipyramidal geometry.

Ponniah S J, Bose SK, Ghosh S.

Dalton Trans. 2012 Apr 7;41(13):3627-9. doi: 10.1039/c2dt30087g. Epub 2012 Feb 24.

PMID:
22362497
16.

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE.

Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11.

17.

AE37: a novel T-cell-eliciting vaccine for breast cancer.

Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE.

Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Review.

PMID:
21895539
18.

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE.

Expert Rev Vaccines. 2011 Feb;10(2):201-10. doi: 10.1586/erv.10.167. Review.

PMID:
21332269
19.

Folate receptor α: a storied past and promising future in immunotherapy.

Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S, Peoples GE.

Hum Vaccin. 2011 Feb;7(2):183-90. Epub 2011 Feb 1. Review.

PMID:
21321484
20.

Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.

Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL.

J Cancer. 2010 Oct 25;1:197-208.

21.

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.

Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE.

Vaccine. 2010 Nov 3;28(47):7476-82. doi: 10.1016/j.vaccine.2010.09.029. Epub 2010 Sep 19.

PMID:
20858449
22.

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE.

Cancer. 2011 Feb 1;117(3):463-71. doi: 10.1002/cncr.25586. Epub 2010 Sep 15.

23.

Cancer Vaccine Development Program collaborations.

Clifton T, Pappas JA, Pavlik M, Papay D, Holmes JP, Ponniah S, Peoples GE.

Mil Med. 2010 Jul;175(7 Suppl):54-6.

PMID:
23634481
24.

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE.

Expert Rev Vaccines. 2010 May;9(5):519-25. doi: 10.1586/erv.10.40. Review.

PMID:
20450326
25.

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE.

J Am Coll Surg. 2010 Feb;210(2):140-7. doi: 10.1016/j.jamcollsurg.2009.10.022. Epub 2009 Dec 22.

PMID:
20113933
26.

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE.

Cancer. 2010 Jan 15;116(2):292-301. doi: 10.1002/cncr.24756.

27.

Therapeutic breast cancer vaccines: a new strategy for early-stage disease.

Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL.

BioDrugs. 2009;23(5):277-87. doi: 10.2165/11313490-000000000-00000. Review.

PMID:
19754218
28.

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE.

Clin Cancer Res. 2009 Apr 15;15(8):2895-904. doi: 10.1158/1078-0432.CCR-08-1126. Epub 2009 Apr 7. Erratum in: Clin Cancer Res. 2009 Sep 1;15(17):5601. Patel, Ritesh [corrected to Patil, Ritesh].

29.

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE.

J Am Coll Surg. 2009 Feb;208(2):193-201. doi: 10.1016/j.jamcollsurg.2008.10.018.

PMID:
19228530
30.
31.

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE.

Cancer. 2008 Oct 1;113(7):1666-75. doi: 10.1002/cncr.23772.

32.

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.

Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE.

J Clin Oncol. 2008 Jul 10;26(20):3426-33. doi: 10.1200/JCO.2007.15.7842.

PMID:
18612158
33.

The E75 HER2/neu peptide vaccine.

Mittendorf EA, Holmes JP, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2008 Oct;57(10):1511-21. doi: 10.1007/s00262-008-0540-3. Epub 2008 Jun 7. Review.

PMID:
18536917
34.

Monitoring circulating tumor cells in cancer vaccine trials.

Gates JD, Benavides LC, Stojadinovic A, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrill GA, Ponniah S, Peoples GE.

Hum Vaccin. 2008 Sep-Oct;4(5):389-92. Epub 2008 Sep 16.

PMID:
18437056
35.

An update on tobacco smoking among New Zealand health care workers, the current picture, 2006.

Ponniah S, Bloomfield A.

N Z Med J. 2008 Apr 18;121(1272):103-5. No abstract available.

PMID:
18425163
36.

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8.

PMID:
18392824
37.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.

Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.

38.

Neural recognition molecules CHL1 and NB-3 regulate apical dendrite orientation in the neocortex via PTP alpha.

Ye H, Tan YL, Ponniah S, Takeda Y, Wang SQ, Schachner M, Watanabe K, Pallen CJ, Xiao ZC.

EMBO J. 2008 Jan 9;27(1):188-200. Epub 2007 Nov 29.

39.

HYOU1/Orp150 expression in breast cancer.

Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M.

Med Sci Monit. 2007 Nov;13(11):BR231-239.

PMID:
17968289
40.

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.

Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.

Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29.

PMID:
17906897
41.

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients.

Hamsher C, Smith AM, Dehqanzada ZA, Khoo S, Ponniah S, Peoples GE, Moroni M.

Cancer Immunol Immunother. 2007 Nov;56(11):1711-21. Epub 2007 Apr 18.

PMID:
17440722
42.

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE.

Oncol Rep. 2007 Mar;17(3):687-94.

PMID:
17273752
43.

Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1.

Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W.

Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1631-6. Epub 2007 Jan 24.

44.

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.

Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Ann Surg Oncol. 2006 Aug;13(8):1085-98. Epub 2006 Jul 24.

PMID:
16865596
45.

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.

PMID:
16783576
46.

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Breast Cancer Res Treat. 2006 Jul;98(1):17-29. Epub 2006 Jun 7.

PMID:
16758122
47.

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.

Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.

Cancer. 2006 Jun 1;106(11):2309-17.

48.

Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.

Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Surgery. 2006 Mar;139(3):407-18.

PMID:
16546506
49.

HER2/neu vaccines in breast cancer.

Khoo S, Ponniah S, Peoples GE.

Womens Health (Lond). 2006 Mar;2(2):217-23. doi: 10.2217/17455057.2.2.217.

PMID:
19803892
50.

Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.

Clin Cancer Res. 2006 Jan 15;12(2):478-86.

Supplemental Content

Loading ...
Support Center